Autolus Therapeutics announces participation in upcoming conferences

Rhea-AI Summary

Autolus Therapeutics plc (Nasdaq: AUTL) will be participating in three upcoming conferences in November. These conferences include the Truist Securities BioPharma Symposium Panel, the Jefferies London Healthcare Conference Fireside Chat, and the Piper Sandler 35th Annual Healthcare Conference Fireside Chat. Autolus Therapeutics' Chief Executive Officer, Dr Christian Itin, will be presenting at all three events.

LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November.

Truist Securities BioPharma Symposium
Panel: Considerations for an Oncology Company’s Autoimmune Side Hustle
Date and time: 9 November 2023, 11:40am ET / 16:40pm GMT
Location: New York, USA
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Jefferies London Healthcare Conference  
Fireside Chat
Date and time: 16 November 2023, 4:00am ET / 9:00am GMT
Location: London, UK
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Piper Sandler 35th Annual Healthcare Conference
Fireside Chat
Date and time: 28 November 2023, 11:30am ET/ 16:30pm GMT
Location: New York, USA
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Find out more information about upcoming events and any webcast and replay details at: https://www.autolus.com/investor-relations/events/

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com

Lauren Williams
Investase
+44 23 9438 7760
lauren@investase.com 

FAQ

What conferences is Autolus Therapeutics participating in November 2023?

Autolus Therapeutics is participating in the Truist Securities BioPharma Symposium Panel, the Jefferies London Healthcare Conference Fireside Chat, and the Piper Sandler 35th Annual Healthcare Conference Fireside Chat.

Who will be presenting at the conferences?

Dr Christian Itin, the Chief Executive Officer of Autolus Therapeutics, will be presenting at all three conferences.

Where and when are the conferences taking place?

The Truist Securities BioPharma Symposium Panel will be held on November 9, 2023, at 11:40am ET / 16:40pm GMT in New York, USA. The Jefferies London Healthcare Conference Fireside Chat will take place on November 16, 2023, at 4:00am ET / 9:00am GMT in London, UK. The Piper Sandler 35th Annual Healthcare Conference Fireside Chat is scheduled for November 28, 2023, at 11:30am ET / 16:30pm GMT in New York, USA.